Related Experiment Video
Updated: Feb 21, 2026
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
Alberto Ballestrero1,2, Davide Bedognetti3, Domenico Ferraioli2,4
1Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Martino IST-Istituto Nazionale Tumori, Genoa, Italy.
Abstract:
SLFN11 is a recently discovered protein with a putative DNA/RNA helicase function. First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors, platinum compounds, and other alkylators, making it an attractive molecule for biomarker development. Later, SLFN11 was linked to antiviral response in human cells and interferon production, establishing a potential bond between immunity and chemotherapy. Recently, we demonstrated the potential role of SLN11 as a biomarker to predict sensitivity to the carboplatin/taxol combination in ovarian cancer. The present manuscript reports on the first international monothematic workshop on SLFN11. Several researchers from around the world, directly and actively involved in the discovery, functional characterization, and study of SLFN11 for its biomarker and medicinal properties gathered to share their views on the current knowledge advances concerning SLFN11. The aim of the manuscript is to summarize the authors' interventions and the main take-home messages resulting from the workshop.
Insights
Schlafen 11 (SLFN11) protein, a DNA/RNA helicase, is linked to chemotherapy resistance and antiviral responses. This workshop summarizes SLFN11 research for biomarker and therapeutic potential.
Area of Science:
- Molecular Biology
- Biochemistry
- Immunology
Background:
- Schlafen 11 (SLFN11) is a protein with DNA/RNA helicase activity, initially linked to thymocyte maturation.
- SLFN11 is causally associated with resistance to DNA-damaging chemotherapy agents, including topoisomerase inhibitors, platinum compounds, and alkylators.
- The protein has also been implicated in antiviral responses and interferon production in human cells.
Framework:
- This manuscript summarizes the proceedings of the first international workshop dedicated to SLFN11.
- Researchers actively involved in SLFN11 discovery and characterization shared insights on its functional properties.
- The workshop focused on advancing the understanding of SLFN11 for potential biomarker and medicinal applications.
Implementation:
- SLFN11's role as a biomarker for predicting sensitivity to carboplatin/taxol chemotherapy in ovarian cancer was recently demonstrated.
- Functional characterization of SLFN11 is ongoing to elucidate its precise mechanisms of action.
- The workshop facilitated discussions on the development of SLFN11 as a therapeutic target or predictive marker.
Implications:
- SLFN11 represents a promising target for overcoming chemotherapy resistance.
- Understanding SLFN11's dual role in cancer and immunity could lead to novel therapeutic strategies.
- Further research on SLFN11 is crucial for its translation into clinical practice as a biomarker or drug target.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023